Research Topics
Genomes and Genes
| Robert R McWilliamsSummaryAffiliation: Mayo Clinic Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancerEvanthia Galanis
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Mol Ther 16:979-84. 2008..5 months from treatment initiation. Rexin-G is well tolerated in doses up to 6 x 10(11) CFU in patients with recurrent pancreatic cancer, but there was no evidence of clinical antitumor activity...
Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 yearsRobert R McWilliams
Division of Medical Oncology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
Cancer 98:356-62. 2003..To help contribute to the management of this disease entity, the authors present herein what to their knowledge is the largest series reported to date in which all patients had biopsy proven confirmation of their brain metastases...- Nucleotide excision repair pathway polymorphisms and pancreatic cancer risk: evidence for role of MMS19LRobert R McWilliams
Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
Cancer Epidemiol Biomarkers Prev 18:1295-302. 2009..Single nucleotide polymorphisms (SNP) in the nucleotide excision repair pathway may encode alterations that affect DNA repair function and therefore influence the risk of pancreatic cancer development... - Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinomaRobert R McWilliams
Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
Cancer 116:203-9. 2010..The purpose of this case-control study was to determine whether CFTR mutations confer a higher risk of pancreatic cancer... - Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma riskRobert R McWilliams
Division of Medical Oncology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
Cancer Res 68:4928-35. 2008..78; 95% CI, 1.28-6.04) or D711D (OR, 2.19; 95% CI, 1.01-4.73). No other significant differences in risk were identified. Minor alleles in DNA repair genes XPF/ERCC4 and XPD/ERCC2 were associated with altered risk for pancreatic cancer... 
Melanoma-induced brain metastasesRobert R McWilliams
Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Expert Rev Anticancer Ther 8:743-55. 2008..Future directions include combined-modality therapy, the incorporation of novel agents, and careful consideration of the structure of clinical trials for this disease...- Obesity adversely affects survival in pancreatic cancer patientsRobert R McWilliams
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer 116:5054-62. 2010..The authors assessed the association of BMI with survival in a sample of pancreatic cancer patients and used epidemiologic and clinical information to understand the contribution of diabetes and hyperglycemia... - Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counselingRobert R McWilliams
Department of Oncology, Mayo Clinic, Rochester, MN, USA
Eur J Hum Genet 19:472-8. 2011..Carriers of germline mutations of CDKN2A should be counseled to avoid tobacco use to decrease risk of pancreatic cancer in addition to taking measures to decrease melanoma risk... - Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancerRobert R McWilliams
Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA
Clin Colorectal Cancer 6:516-21. 2007..A combination regimen using all 4 agents could potentially increase response rates in CRC... - Polymorphic variants in hereditary pancreatic cancer genes are not associated with pancreatic cancer riskRobert R McWilliams
Department of Oncology, Mayo Clinic, 200 First Street, Southwest, Rochester, MN 55905, USA
Cancer Epidemiol Biomarkers Prev 18:2549-52. 2009..We hypothesized that common variants in these genes, single nucleotide polymorphisms (SNP), may also influence risk for pancreatic cancer development... - Treatment of brain metastases from melanomaRobert R McWilliams
Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 78:1529-36. 2003..Chemotherapy may be gaining a role with newer agents that penetrate the blood-brain barrier. Combined modality therapy appears to be the future direction of treatment of multiple metastases... - Novel therapeutics in colorectal cancerRobert R McWilliams
Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Dis Colon Rectum 48:1632-50. 2005..We also suggest appropriate clinical settings for specific targets and outline future directions of research... - Risk of malignancy in first-degree relatives of patients with pancreatic carcinomaRobert R McWilliams
Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Cancer 104:388-94. 2005..Counseling the families of PC patients regarding their risk of cancer remains problematic because little information is available... - Treatment options for brain metastases from melanomaRobert R McWilliams
Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
Expert Rev Anticancer Ther 5:809-20. 2005..Future directions include combined modality therapy, the incorporation of novel agents and careful consideration of the structure of clinical trials for this disease... - Association of family history of specific cancers with a younger age of onset of pancreatic adenocarcinomaRobert R McWilliams
Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Clin Gastroenterol Hepatol 4:1143-7. 2006..Pancreatic adenocarcinoma has been associated with several familial cancer syndromes that also predispose to other malignancies. Younger ages of onset of pancreatic cancer (PC) have been reported in families with these syndromes... - Association of breast cancer susceptibility variants with risk of pancreatic cancerFergus J Couch
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer Epidemiol Biomarkers Prev 18:3044-8. 2009..Recently, several breast cancer susceptibility loci have been identified through genome-wide association studies. Here we evaluated possible associations between these single nucleotide polymorphisms (SNP) and pancreatic cancer risk... - Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatmentSvetomir N Markovic
Division of Hematology, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 82:490-513. 2007..Although much work remains to be done to improve the survival of patients with melanoma, clinically meaningful results seem within reach... - A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775Lisa A Kottschade
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Cancer 119:586-92. 2013..Increasing evidence shows chemotherapy in combination with vascular endothelial growth factor (VEGF) inhibition is a clinically active therapy for patients with metastatic melanoma (MM)... - Association of mitotic regulation pathway polymorphisms with pancreatic cancer risk and outcomeFergus J Couch
Department of Laboratory Medicine and Pathology, Stabile 2 42, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
Cancer Epidemiol Biomarkers Prev 19:251-7. 2010..Single nucleotide polymorphisms (SNP) in regulators of mitosis may promote chromosome missegregation and influence pancreatic cancer and/or survival... - A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1)Lisa A Kottschade
Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
Cancer 117:1704-10. 2011..ABI-007 is an albumin-bound formulation of paclitaxel that has demonstrated single-agent activity against metastatic melanoma... - Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005)Michele M Corsini
Department of Radiation Oncology the Division of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 26:3511-6. 2008..To determine prognostic factors and impact of adjuvant chemotherapy (CT) and radiotherapy (RT) on overall survival (OS) after resection of pancreatic adenocarcinoma... - Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccineMatthew S Block
Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Melanoma Res 21:438-45. 2011..The increase in T regulatory cells associated with interleukin-2 treatment suggests that interleukin-2 may be immunosuppressive in this setting... - Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943Steven R Alberts
Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
J Gastrointest Cancer 38:87-94. 2007..To determine the maximum tolerated dose (MTD) and efficacy of pemetrexed and gemcitabine in patients with either biliary tract or gallbladder carcinoma... - Fluctuation of systemic immunity in melanoma and implications for timing of therapyAlexey A Leontovich
Department of Health Science Research, Mayo Clinic, Rochester, MN 55901, USA
Front Biosci (Elite Ed) 4:958-75. 2012..Individualized conventional chemotherapy delivery by synchronizing treatment with pre-existing patient-specific biorhythms may improve clinical outcomes in metastatic melanoma... - A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanomaSvetomir N Markovic
Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Am J Clin Oncol 30:303-9. 2007..We conducted a phase II trial evaluating the clinical efficacy of ABT-510 and its effects on biomarkers of angiogenesis and immunity in patients with metastatic melanoma (MM)... - A single-institution experience with 491 cases of small bowel adenocarcinomaThorvardur R Halfdanarson
Department of Oncology, Mayo Clinic, Rochester, MN, USA
Am J Surg 199:797-803. 2010..The optimal treatment of small bowel adenocarcinoma is unknown... - A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33Gloria M Petersen
Department of Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
Nat Genet 42:224-8. 2010..19, 95% CI 1.11-1.27), maps to the CLPTM1L-TERT locus on 5p15.33, which is associated with multiple cancers. Our study has identified common susceptibility loci for pancreatic cancer that warrant follow-up studies... - Are cancer survivors/patients knowledgeable about osteoporosis? Results from a survey of 285 chemotherapy-treated cancer patients and their companionsHeidi McKean
Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
J Nutr Educ Behav 40:144-8. 2008..This study assessed osteoporosis knowledge deficits among cancer patients and their spouses/partners... - Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosisSvetomir N Markovic
Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 82:364-80. 2007..Part 2 (which will appear in the April 2007 issue) will review melanoma staging, prognosis, and treatment... - GLI1 inhibition promotes epithelial-to-mesenchymal transition in pancreatic cancer cellsSimon Joost
Institute of Molecular Biology and Tumor Research, Philipps University, Marburg, Germany
Cancer Res 72:88-99. 2012.... - Factors influencing receptivity to future screening options for pancreatic cancer in those with and without pancreatic cancer family historyCarmen Radecki Breitkopf
Mayo Clinic College of Medicine, Department of Health Sciences Research, Charlton 6, 200 First Street SW, Rochester, MN, 55905, USA
Hered Cancer Clin Pract 10:8. 2012..abstract:.. - Fluorescence in situ hybridization to visualize genetic abnormalities in interphase cells of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreasGordon W Dewald
Division of Laboratory Genetics, Mayo Clinic, Rochester, MN 55905, USA
Mayo Clin Proc 84:801-10. 2009..To use fluorescence in situ hybridization (FISH) to visualize genetic abnormalities in interphase cell nuclei (interphase FISH) of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas... - Malignant melanoma in the 21st century: the emerging molecular landscapeAleksandar Sekulic
Department of Dermatology, Mayo Clinic, Scottsdale, AZ 85259, USA
Mayo Clin Proc 83:825-46. 2008..We review the emerging molecular landscape of melanoma and its implications for better management of patients with melanoma... - Percutaneous cryoablation of musculoskeletal oligometastatic disease for complete remissionBrendan P McMenomy
Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
J Vasc Interv Radiol 24:207-13. 2013..To assess the safety and effectiveness of percutaneous cryoablation to treat limited metastases to the musculoskeletal system, with the goal of complete disease remission... - Capecitabine and temozolomide: design, implementation, and preliminary outcomes from a pilot project to ensure safe prescribing of oral chemotherapyAminah Jatoi
Division of Medical Oncology, Mayo Clinic, Rochester, MN
J Oncol Pract 6:210-2. 2010..Without adequate safety measures, oral chemotherapy can lead to undetected dosing errors. The Mayo Clinic launched a project to ensure that all capecitabine and temozolomide prescriptions receive an independent double check... - Gemcitabine plus cisplatin in advanced pancreatic cancerRobert R McWilliams
J Clin Oncol 25:1142; author reply 1142-3. 2007 - Mitochondrial genetic polymorphisms do not predict survival in patients with pancreatic cancerThorvardur R Halfdanarson
Department of Internal Medicine, Division of Hematology, Oncology and Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA
Cancer Epidemiol Biomarkers Prev 17:2512-3. 2008..After adjusting for covariates and multiple comparisons, no association between any of the mitochondrial single nucleotide polymorphisms or haplogroups and survival was observed...
Research Grants
- Genetic Epidemiology of Young-Onset Pancreatic CancerRobert McWilliams; Fiscal Year: 2007..This proposed research is 100% relevant to pancreatic cancer. ..